B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-LifeElisa Fiorito, Jostein Dahle, Geir E. Tjønnfjord et al.|Blood|2022Cited by 0
NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell MalignanciesRoman Generalov, Jostein Dahle, Elisa Fiorito et al.|Blood|2022Cited by 0
NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHLRoman Generalov, Jostein Dahle, Sigrid S. Skånland et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0